VRNA - Verona Pharma plc

106.91
0.120   0.112%

Share volume: 1,871,959
Last Updated: 10-06-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$106.79
0.12
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 32%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0.57%
1 Year
65.37%
2 Year
68.31%
Key data
Stock price
$106.91
P/E Ratio 
0.00
DAY RANGE
$106.81 - $106.93
EPS 
-$0.05
52 WEEK RANGE
$47.20 - $106.93
52 WEEK CHANGE
$74.26
MARKET CAP 
8.052 B
YIELD 
N/A
SHARES OUTSTANDING 
775.729 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: David S. Zaccardelli
Region: US
Website: veronapharma.com
Employees: 30
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Verona Pharma plc focuses on development and commercialization of therapies for respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Enfentrine is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Recent news